I am on a par with you as to being a biotech expert. I do not consider my figures pure Pollyanna thinking and I will explain why. Overall, I can't believe the number of people that believe in the science as the greatest to come down the pike and then turn right around and say that we should sell it just like any other piece of sh%% drug from a historical perspective that had numerous severe side effects and iffy efficacy.
There is no doubt in my mind we have first-in-class drugs for the indications they have been tested for to date. If someone does not believe that, then that would be a major factor why they value it so much lower than me.
Secondly, other than Humira (and possibly some other biologics) name a drug that has the scope of indications across so many areas of medicine as does ALL our drugs - Kevetrin (All of cancer with heavy, heavy weight as a perfect combinatory drug), Prurisol (Dermatologic (Acne, Eczema, other more severe skin lesion conditions), AutoImmune (100 diseases/conditions in this area to include Psoriasis), and Brilicidin (Anti-inflammatory, IBD, OM, industrial uses via it as a polymer in paints, materials, and plastics and this is just the tip of the iceberg IMO as to the overall scope of possible uses). Add up all the possible uses of all three drugs and you have revenue potential of easily over $100B/yr)
Thirdly, the drugs at the current time are in a "Perfect Storm" as to financial/timing factors as many BPs are flush with cash, bare with R&D pipelines, close to the end of patent-protected name drugs, and looking eagerly to solve these problems that put their future at risk.
Fourth, many spout the historical viewpoint that the large amounts I discuss have never been done before - well, business has changed in the 21st century and we have seen the never-seen-before nearly overnight monsters of Apple, Google, Facebook, other high tech concerns, etc and the world is now aware that changes no longer take decades but are lightning fast and when the real deal comes along you only have one chance to grab it. You snooze, you lose. IPIX is in a unique position with a pipeline that is unquestionably as strong as there has ever been in biotech startup history. In my mind, when I hear the history minded individuals give their opinions it is like someone lecturing me on warfare using WWI weapons and strategy as their battle plans and I am using laser/satellite weapons. They may be correct, but IMO the future is for visionaries, not those concentrating on the rear view mirror.
Fifth, mgt is usually the weak link in startups and they sell stockholders down the tubes for their own gain the vast majority of the time. Our mgt members are the largest shareholders so their goals are perfectly aligned with ours and this has been shown by Leo as he has been tightfisted in raising any more money than absolutely necessary and IMO has kept the share count at a remarkably low level for the stage of development we currently are in for all three of our drugs. IMO they are like a fourth drug for shareholders in that they provide that much value to IPIX.
I may be so off base it is laughable, but I feel extremely confident that my vision will be much closer to what occurs than those playing IPIX as a penny stock and looking at $3-4 as a great investment.
There is no doubt in my mind we have first-in-class drugs for the indications they have been tested for to date. If someone does not believe that, then that would be a major factor why they value it so much lower than me.
Secondly, other than Humira (and possibly some other biologics) name a drug that has the scope of indications across so many areas of medicine as does ALL our drugs - Kevetrin (All of cancer with heavy, heavy weight as a perfect combinatory drug), Prurisol (Dermatologic (Acne, Eczema, other more severe skin lesion conditions), AutoImmune (100 diseases/conditions in this area to include Psoriasis), and Brilicidin (Anti-inflammatory, IBD, OM, industrial uses via it as a polymer in paints, materials, and plastics and this is just the tip of the iceberg IMO as to the overall scope of possible uses). Add up all the possible uses of all three drugs and you have revenue potential of easily over $100B/yr)
Thirdly, the drugs at the current time are in a "Perfect Storm" as to financial/timing factors as many BPs are flush with cash, bare with R&D pipelines, close to the end of patent-protected name drugs, and looking eagerly to solve these problems that put their future at risk.
Fourth, many spout the historical viewpoint that the large amounts I discuss have never been done before - well, business has changed in the 21st century and we have seen the never-seen-before nearly overnight monsters of Apple, Google, Facebook, other high tech concerns, etc and the world is now aware that changes no longer take decades but are lightning fast and when the real deal comes along you only have one chance to grab it. You snooze, you lose. IPIX is in a unique position with a pipeline that is unquestionably as strong as there has ever been in biotech startup history. In my mind, when I hear the history minded individuals give their opinions it is like someone lecturing me on warfare using WWI weapons and strategy as their battle plans and I am using laser/satellite weapons. They may be correct, but IMO the future is for visionaries, not those concentrating on the rear view mirror.
Fifth, mgt is usually the weak link in startups and they sell stockholders down the tubes for their own gain the vast majority of the time. Our mgt members are the largest shareholders so their goals are perfectly aligned with ours and this has been shown by Leo as he has been tightfisted in raising any more money than absolutely necessary and IMO has kept the share count at a remarkably low level for the stage of development we currently are in for all three of our drugs. IMO they are like a fourth drug for shareholders in that they provide that much value to IPIX.
I may be so off base it is laughable, but I feel extremely confident that my vision will be much closer to what occurs than those playing IPIX as a penny stock and looking at $3-4 as a great investment.
10
